• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

18.03 UNCHANGED
Official Closing Price Updated: 7:00 PM EDT, Aug 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,809,973
Open 18.00
Bid (Size) 18.25 (200)
Ask (Size) 18.35 (200)
Prev. Close 18.03
Today's Range 17.96 - 18.11
52wk Range 12.99 - 18.89
Shares Outstanding 1,557,765,596
Dividend Yield 3.76%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
August 28, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
August 24, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire

Performance

YTD
+15.4%
+15.4%
1 Month
+5.5%
+5.5%
3 Month
+18.7%
+18.7%
6 Month
-2.2%
-2.2%
1 Year
+18.9%
+18.9%

More News

Read More
News headline image
Takeda (TAK) Q1 2026 Earnings Call Transcript ↗
August 07, 2026
Via The Motley Fool
Topics Earnings
News headline image
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
August 05, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Pharmaceutical Q1 Earnings Call Highlights ↗
July 30, 2026
Via MarketBeat
Topics Earnings
News headline image
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
July 30, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
July 16, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
July 12, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
June 24, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
June 15, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
June 11, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
June 09, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
May 18, 2026
From Hagens Berman
Via Business Wire
News headline image
Takeda Pharmaceutical Q4 Earnings Call Highlights ↗
May 15, 2026
Via MarketBeat
Topics Earnings
News headline image
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
May 13, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Novavax (NVAX) Q2 2025 Earnings Transcript ↗
May 06, 2026
Via The Motley Fool
News headline image
Why Did Axsome Therapeutics Stock Hit Another Record High Today? ↗
May 04, 2026
Via The Motley Fool
News headline image
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
May 04, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
April 06, 2026
Via MarketMinute
News headline image
The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals
March 31, 2026
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
March 28, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
March 26, 2026
Via Finterra
Topics Economy Initial Public Offering
News headline image
The Great Resurgence: A Deep Dive into Grifols S.A. (GRFS) in 2026
March 25, 2026
Via Finterra
Topics Bankruptcy Economy Lawsuit
News headline image
The Great Unbundling: How AI’s Insatiable Hunger is Driving a Corporate Divestiture Gold Rush
March 18, 2026
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
March 02, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire

Frequently Asked Questions

Is Takeda Pharmaceutical Company Limited American Depositary Shares (each publicly traded?
Yes, Takeda Pharmaceutical Company Limited American Depositary Shares (each is publicly traded.
What exchange does Takeda Pharmaceutical Company Limited American Depositary Shares (each trade on?
Takeda Pharmaceutical Company Limited American Depositary Shares (each trades on the New York Stock Exchange
What is the ticker symbol for Takeda Pharmaceutical Company Limited American Depositary Shares (each?
The ticker symbol for Takeda Pharmaceutical Company Limited American Depositary Shares (each is TAK on the New York Stock Exchange
What is the current price of Takeda Pharmaceutical Company Limited American Depositary Shares (each?
The current price of Takeda Pharmaceutical Company Limited American Depositary Shares (each is 18.03
When was Takeda Pharmaceutical Company Limited American Depositary Shares (each last traded?
The last trade of Takeda Pharmaceutical Company Limited American Depositary Shares (each was at 08/28/26 07:00 PM ET
What is the market capitalization of Takeda Pharmaceutical Company Limited American Depositary Shares (each?
The market capitalization of Takeda Pharmaceutical Company Limited American Depositary Shares (each is 28.09B
How many shares of Takeda Pharmaceutical Company Limited American Depositary Shares (each are outstanding?
Takeda Pharmaceutical Company Limited American Depositary Shares (each has 28B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap